
|Videos|October 6, 2017
What Are the Results of the REVIVE-2 Trial?
Author(s)Contagion® Editorial Staff
David Huang, PhD, MD, shares the recent results of the REVIVE-2 trial.
Advertisement
David Huang, PhD, MD, chief medical officer at Motif Bio, shares the recent results of the REVIVE-2 trial.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Advertisement
Advertisement
Trending on Contagion Live
1
Is 4 Weeks of Glecaprevir/Pibrentasvir Sufficient to Treat Early Hepatitis C Infection?
2
Antibiotic Shows Promise in Treating Gram-Positive Pneumonia, Including in High-Risk Patients
3
Vaccines as a Secondary Strategy in the Fight Against Antimicrobial Resistance
4
As NDM-CRE Infections Rise Significantly, Diagnostic Access Emerges as Weak Link
5